Literature DB >> 10954781

Development and application of a synthetic peptide-based osteocalcin assay for the measurement of bone formation in mouse serum.

A K Srivastava1, G Castillo, J E Wergedal, S Mohan, D J Baylink.   

Abstract

The mouse is frequently used as an animal model to study skeletal mechanisms relevant to humans. Biochemical markers of bone formation and resorption provide one of the key parameters for assessing skeletal metabolism. One biochemical marker that has proven to be useful in the studies of mouse skeletal metabolism is osteocalcin. Assay for osteocalcin is available in the mouse. The present study describes development of an osteocalcin radioimmunoassay (RIA) using a synthetic peptide. Intact osteocalcin purified from mouse bone extracts shows parallel displacement with synthetic peptide. Sensitivity of the RIA was 19 ng/ml. The average (n = 9) intra- and interassay coefficient of variation for two controls was less than 10%; the averaged recoveries were 106%. The osteocalcin concentration measured by peptide RIA shows a high correlation (r = 0.88, n = 117, P < 0.0001) with an intact osteocalcin assay. In addition, when the intact assay and peptide assays were applied to evaluate skeletal perturbation, similar results were obtained. Accordingly, osteocalcin levels measured by both intact and peptide-based RIA in 8-week C57BL/6J (n = 8) mice treated with PTH 1-34 were twofold higher compared with the vehicle-treated control group. Further studies of the application of the peptide-based RIA for osteocalcin revealed that osteocalcin levels in 4-week postovariectomized (OVX) C57BL/6N mice (n = 10) were 80% higher than the sham-operated (n = 10) mice receiving vehicle. OVX mice receiving weekly injections of estradiol (400 microg/kg body weight) were 38% lower compared with the OVX group treated with vehicle. In conclusion, the peptide-based RIA has analytical and a discriminative power similar to that of the intact osteocalcin assay but has the advantage that the resources for this assay are much easier to accrue.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10954781     DOI: 10.1007/s002230001109

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  5 in total

1.  Elevated plasma phenylalanine concentrations may adversely affect bone status of phenylketonuric mice.

Authors:  S Yannicelli; D M Medeiros
Journal:  J Inherit Metab Dis       Date:  2002-09       Impact factor: 4.982

2.  Isozyme profile and tissue-origin of alkaline phosphatases in mouse serum.

Authors:  Cecilia Halling Linder; Ulrika H Englund; Sonoko Narisawa; José Luis Millán; Per Magnusson
Journal:  Bone       Date:  2013-01-10       Impact factor: 4.398

3.  Evidence that IGF-binding protein-5 functions as a growth factor.

Authors:  N Miyakoshi; C Richman; Y Kasukawa; T A Linkhart; D J Baylink; S Mohan
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

4.  Benchmark experimental data set and assessment of adsorption free energy for peptide-surface interactions.

Authors:  Yang Wei; Robert A Latour
Journal:  Langmuir       Date:  2009-05-19       Impact factor: 3.882

5.  Undercarboxylated osteocalcin inhibits the early differentiation of osteoclast mediated by Gprc6a.

Authors:  Hailong Wang; Jinqiao Li; Zihan Xu; Feng Wu; Hongyu Zhang; Chao Yang; Jian Chen; Bai Ding; Xiukun Sui; Zhifeng Guo; Yinghui Li; Zhongquan Dai
Journal:  PeerJ       Date:  2021-03-02       Impact factor: 2.984

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.